2005•Xinxueguan kangfu yixue zazhiRequires access
Efficacy and safety of Tongxinluo capsule in patients with acute coronary syndrome
Sun Yang-li
Open publisher page 1 citations
Abstract
Objective: To observe the efficacy and safety of Tongxinluo capsule in patients with acute coronary syndrome (ACS). Methods; The 77 ACS patients were randomly divided into Tongxinluo group (n = 39)and control group (n = 38) .In Tongxinluo group patients received routine anti-ACS treatment and Tongxinluo; the patients in control group were only treated by routine anti-ACS treatment; the followed time was 1 year. Results:For release ACS symptom, the efficiency of Tongxinluo group and control group was 89. 7% and 68. 4% respectively (P0. 05) ;for improve ischemic ST-T changes in ECG, the efficiency of Tongxinluo group and control group was 58. 9% and 39. 5% respectively (P0. 05). The active of thrombin and fibrinogen level decreased (P0. 05) ,the LVEF,left ventricula shortening fraction (FS) and E/A ratio after 6 months increased (P0. 05) in Tongxinluo group compared with control group. The anginarec, heart failure and PTCA/CABG of Tongxinluo group were less than those of control group (P0. 05) .The side effect of Tongxinluo group was few. Conclusion: On the basis of routine anti-ACS treatment to take Tongxinluo capsule is an efficacy and saft treatment, may prevent cardio-brain vascular events.